For pharmaceutical and life sciences companies, ESG is increasingly becoming a business-management issue rather than a standalone sustainability initiative.
The reason is straightforward: pharmaceutical companies operate across complex supply chains, highly regulated manufacturing environments, energy-intensive facilities, sensitive products, stringent quality systems, and increasingly demanding customer and investor expectations.
A company may already have systems for quality, environment, occupational health and safety, energy, supplier management and risk. The challenge is bringing these elements together into an ESG approach that is measurable, evidence-based and aligned with business priorities.
For pharmaceutical and life sciences leaders, the question is therefore not simply “How do we report on ESG?”
It is:
“How do we build the processes, data, governance and evidence needed to demonstrate responsible business performance?”
This article explains a practical approach to preparing for evolving ESG requirements, including the role of ISO management systems, supplier assessments such as EcoVadis, ESG risk management and operational improvement.
Important: ESG requirements vary by jurisdiction, company size, ownership structure, customer expectations and applicable reporting frameworks. Businesses should verify which legal and reporting obligations apply to them rather than assuming that one ESG framework applies universally.
What Are ESG Requirements for Pharmaceutical Companies?
ESG requirements refer broadly to the environmental, social and governance expectations, disclosures, assessments and controls that apply to an organization.
For pharmaceutical and life sciences businesses, these areas can include:
| ESG Dimension | Relevant Pharmaceutical Considerations |
|---|---|
| Environmental | Energy consumption, greenhouse-gas emissions, water, waste, chemicals, effluent and resource efficiency |
| Social | Worker health and safety, labour practices, human rights, employee development and responsible supply chains |
| Governance | Ethics, compliance, risk management, policies, accountability, data controls and responsible business conduct |
| Supply Chain | Supplier ESG screening, procurement practices, traceability and third-party risks |
| Reporting & Evidence | Policies, procedures, KPIs, records, assessments and supporting documentation |
The specific requirements depend on the company’s circumstances.
For example, an export-oriented pharmaceutical manufacturer may face ESG expectations from multinational customers even when a particular statutory reporting requirement does not directly apply to the company.
This is why ESG preparation should not be treated solely as a reporting exercise.
Why Does ESG Matter to Pharmaceutical and Life Sciences Businesses?
1. Supply-Chain Expectations Are Increasing
Pharmaceutical companies often depend on extensive networks of raw-material suppliers, contract manufacturers, logistics providers, packaging suppliers and other business partners.
Large customers may assess suppliers on environmental, social and governance criteria.
Consequently, a company’s ESG maturity can influence its ability to respond to customer questionnaires, supplier assessments and procurement requirements.
2. Environmental Performance Can Affect Operating Costs
Manufacturing facilities consume energy and resources.
Electricity, steam, compressed air, HVAC systems, water, refrigeration and process equipment can all contribute to operating costs and environmental impact.
Energy and resource-management initiatives can therefore have both environmental and operational dimensions.
3. ESG Is Connected to Enterprise Risk
Environmental incidents, labour issues, supplier disruptions, unethical conduct or weak governance controls can create financial and reputational consequences.
An effective ESG program should therefore connect with the organization’s existing risk-management processes rather than operate as a separate administrative activity.
4. Evidence Matters
One of the most common challenges is the difference between having a policy and being able to demonstrate implementation.
For example:
- A company may have an environmental policy but lack consistent environmental KPIs.
- It may have a supplier code of conduct but not systematically assess suppliers.
- It may report energy consumption but lack documented reduction objectives.
- It may conduct employee training without measuring completion and effectiveness.
ESG readiness requires evidence as well as commitments.
Key ESG Challenges for Pharmaceutical Companies
Fragmented ESG Data
ESG information may sit across:
- EHS
- HR
- Procurement
- Finance
- Quality
- Operations
- Facilities
- Compliance
- Supply Chain
- Senior Management
Without clear ownership, data collection can become inconsistent.
Complex Supplier Networks
A pharmaceutical company’s environmental and social risks can extend beyond its own facilities.
Suppliers may differ significantly in their maturity, documentation and ability to provide ESG information.
Lack of Measurable Objectives
Broad commitments such as “become more sustainable” are difficult to manage.
Management needs measurable objectives, defined baselines, responsibilities and review mechanisms.
Difficulty Converting ESG Into Business Processes
ESG can become ineffective when it exists mainly in presentations and annual reports.
The more useful approach is to embed relevant ESG considerations into procurement, operational controls, risk assessments, management reviews and improvement projects.
Changing External Expectations
Reporting standards, customer questionnaires, investor expectations and regulatory requirements can evolve.
Companies therefore need a process for monitoring applicable requirements rather than relying on a one-time ESG exercise.
How Businesses Can Address These Challenges
1. Determine Which Requirements Actually Apply
Start with an applicability assessment.
Map:
- Countries and markets served
- Legal entities
- Company size and ownership
- Reporting obligations
- Customer requirements
- Investor requirements
- Contractual ESG requirements
- Relevant industry expectations
- Applicable reporting frameworks
This prevents organizations from investing resources in requirements that are irrelevant while overlooking requirements that actually affect the business.
2. Conduct an ESG Gap Assessment
Compare the current state with applicable expectations.
A practical gap assessment can examine:
| Area | Current State | Desired State | Gap |
|---|---|---|---|
| ESG Governance | Informal ownership | Defined accountability | Medium |
| Energy | Consumption monitored | Targets and improvement plans | High |
| Supplier ESG | Limited screening | Risk-based assessment | High |
| Employee HSE | Existing controls | ESG-linked metrics | Low |
| ESG Data | Multiple sources | Controlled data process | Medium |
The assessment should distinguish between:
Policy gaps → Process gaps → Performance gaps → Evidence gaps
That distinction makes the resulting action plan much more practical.
3. Establish ESG Governance
Assign clear responsibility.
A typical structure could include:
Board / Senior Management
↓
ESG Steering Committee
↓
Functional Owners
- EHS
- HR
- Procurement
- Quality
- Operations
- Finance
- Compliance
- Supply Chain
↓
Data Owners and Process Owners
The objective is not to create unnecessary bureaucracy.
It is to establish accountability for decisions, data and improvement actions.
4. Build an ESG Data Inventory
Identify what the organization needs to measure and where the information comes from.
Examples include:
- Electricity consumption
- Fuel consumption
- Renewable-energy use
- Water consumption
- Waste generation
- Waste disposal
- Greenhouse-gas emissions
- Occupational incidents
- Employee training
- Diversity indicators
- Supplier assessments
- Business ethics training
- Compliance incidents
Each KPI should ideally have:
Definition → Data Source → Owner → Frequency → Calculation Method → Evidence → Review Mechanism
This is particularly important when ESG information may eventually be used for external reporting or customer assessments.
5. Assess the Supply Chain
A risk-based supplier ESG process can include:
- Categorize suppliers by risk.
- Identify critical suppliers.
- Define relevant ESG criteria.
- Issue supplier questionnaires where appropriate.
- Review supporting evidence.
- Identify gaps.
- Develop supplier improvement plans.
- Monitor progress.
Not every supplier requires the same depth of assessment.
A risk-based approach can help organizations focus resources where potential exposure is greatest.
6. Integrate ESG With Existing Management Systems
Pharmaceutical companies frequently already operate structured management systems.
Instead of creating an entirely separate ESG bureaucracy, organizations can identify where existing systems can support ESG objectives.
ISO 14001
Environmental management processes can support areas such as:
- Environmental aspects and impacts
- Compliance obligations
- Operational controls
- Objectives
- Monitoring
- Corrective action
- Continual improvement
ISO 9001
Quality-management principles can contribute through:
- Process ownership
- Risk-based thinking
- Documented information
- Performance monitoring
- Corrective action
- Continual improvement
Occupational Health & Safety
Worker safety is an important social dimension.
Existing HSE processes can provide evidence around:
- Hazard identification
- Risk assessment
- Incident management
- Worker training
- Emergency preparedness
- Safety performance
Energy Management
Energy-intensive pharmaceutical facilities can evaluate energy performance through systematic measurement and improvement.
Energy-management practices can connect environmental objectives with operational efficiency.
The Role of EcoVadis in ESG Readiness
For companies participating in customer or supply-chain sustainability assessments, EcoVadis may be relevant.
EcoVadis assessments generally examine sustainability-related management practices across areas such as environment, labour and human rights, ethics, and sustainable procurement.
The practical lesson is important:
An assessment should not become a document-collection exercise performed immediately before submission.
A stronger approach is to build the underlying management practices throughout the year.
For example:
Policy → Procedure → Implementation → KPI → Evidence → Review → Improvement
This creates a more sustainable foundation for responding to external assessments.
Practical Business Example
Hypothetical Example: Pharmaceutical Manufacturing Facility
This is a hypothetical example and is not an ASPM Consulting client case.
Consider a pharmaceutical manufacturing facility with annual electricity expenditure of ₹2 crore.
An initial energy review identifies opportunities involving HVAC optimization, operating practices and equipment efficiency.
Suppose management establishes an improvement target of 8% reduction in electricity consumption, subject to technical validation.
Starting Situation
Annual electricity cost: ₹2 crore
Target reduction: 8%
Potential annual cost reduction:
₹2 crore × 8% = ₹16 lakh
If the improvement can be achieved without compromising product quality, validated processes, safety or regulatory requirements, the organization could potentially reduce annual electricity expenditure by approximately ₹16 lakh.
Why This Matters for ESG
The initiative has several dimensions:
- Environmental: lower energy consumption
- Financial: lower operating cost
- Operational: improved equipment and process efficiency
- Governance: measurable objective and management review
- ESG evidence: documented baseline, target and performance
However, ₹16 lakh should be treated as an illustrative calculation, not a guaranteed saving. Actual results depend on tariffs, production volumes, operating conditions, project costs and the effectiveness of implemented measures.
ESG and ROI: A Simple Business Framework
Where financial benefits can reasonably be quantified:
Annual Savings = Current Annual Cost − Improved Annual Cost
For example:
Current annual energy cost: ₹2 crore
Improved annual energy cost: ₹1.84 crore
Therefore:
Annual Savings = ₹2 crore − ₹1.84 crore = ₹16 lakh
For an investment-based project, management can also examine:
Simple Payback Period = Project Investment ÷ Annual Savings
If the hypothetical improvement required ₹32 lakh of investment:
Payback Period = ₹32 lakh ÷ ₹16 lakh = 2 years
This calculation does not replace a detailed financial evaluation. Production changes, maintenance costs, financing costs, depreciation, implementation risks and other factors may need to be considered.
Common Mistakes Businesses Make
1. Treating ESG as a Reporting Project
Reporting is only one component. The underlying policies, processes and performance need to exist first.
2. Collecting Data Without Defining Ownership
Numbers without clear definitions and accountable owners can become difficult to verify.
3. Creating Ambitious Targets Without Baselines
A target should have a defensible starting point and an appropriate measurement method.
4. Ignoring Suppliers
A company’s ESG exposure may extend into its supply chain.
5. Maintaining Policies Without Implementation Evidence
A signed policy does not necessarily demonstrate effective implementation.
6. Creating a Separate ESG System Unnecessarily
Existing ISO, HSE, quality, procurement and risk-management processes may already provide useful foundations.
7. Waiting Until an Assessment or Customer Questionnaire Arrives
Reactive preparation can create unnecessary pressure and inconsistent evidence.
Implementation Checklist
Business leaders can use the following checklist to assess ESG readiness:
- Identify applicable ESG requirements and stakeholder expectations.
- Map relevant environmental, social and governance topics.
- Assign executive and functional ownership.
- Conduct an ESG gap assessment.
- Establish measurable objectives and baselines.
- Create an ESG KPI and data inventory.
- Define data owners and calculation methods.
- Review energy, water, waste and emissions performance.
- Assess relevant labour and HSE practices.
- Review business ethics and governance controls.
- Develop a risk-based supplier ESG assessment process.
- Map existing ISO and management-system controls to ESG requirements.
- Establish evidence-retention practices.
- Review ESG performance periodically.
- Maintain a continual-improvement action plan.
How ASPM Consulting Can Help
For pharmaceutical and life sciences companies, ESG preparation can be approached through a structured consulting cycle:
Assessment
Review current ESG practices, management systems, documentation, data and stakeholder requirements.
Strategy
Prioritize material ESG issues and develop practical objectives, responsibilities and improvement priorities.
Implementation
Integrate relevant ESG requirements with existing systems such as ISO, EHS, energy management, risk management and supply-chain processes.
Measurement
Establish appropriate KPIs, data ownership, monitoring mechanisms and evidence.
Continual Improvement
Use management reviews, audits, corrective actions and improvement projects to strengthen ESG performance over time.
ASPM Consulting’s relevant expertise includes ESG and sustainability, EcoVadis consulting, ISO management systems, risk advisory, energy management and operational excellence. The appropriate combination depends on the organization’s industry, operating model, customer requirements and applicable obligations.
The objective should not simply be to “prepare for an ESG assessment.”
It should be to develop management practices that remain useful after the assessment is complete.
Conclusion
For pharmaceutical and life sciences companies, ESG readiness is increasingly connected to operational discipline, supply-chain resilience, risk management, environmental performance and stakeholder expectations.
The most practical starting point is not another ESG presentation.
It is a structured assessment of:
What applies? → What do we already have? → Where are the gaps? → Who owns them? → How will we measure progress?
Organizations that connect ESG with existing management systems can potentially reduce duplication while creating stronger processes for measurement, accountability and continual improvement.
For companies beginning their ESG journey, an objective gap assessment can provide a practical starting point for prioritizing the next steps.
Practical Checklist
ESG Readiness Checklist for Pharmaceutical & Life Sciences Companies
| Area | Key Question |
|---|---|
| Applicability | Which ESG requirements actually apply to our organization? |
| Governance | Who is accountable for ESG performance? |
| Materiality | Which ESG topics are most relevant to our business and stakeholders? |
| Data | Do we have reliable ESG data and defined calculation methods? |
| Environment | Are energy, water, waste and emissions being measured appropriately? |
| People | Are HSE, labour and employee-related risks systematically managed? |
| Supply Chain | Are critical suppliers assessed for relevant ESG risks? |
| Governance | Are ethics, compliance and risk controls documented and monitored? |
| Evidence | Can we substantiate our ESG claims with records? |
| Improvement | Are ESG gaps translated into measurable improvement actions? |
FAQs
What are the main ESG requirements for pharmaceutical companies?
There is no single ESG requirement applicable to every pharmaceutical company. Requirements can arise from legislation, reporting obligations, customers, investors, supply-chain assessments and voluntary frameworks. Companies should first determine which obligations and stakeholder expectations apply to their specific legal entities, markets and business relationships.
Why is ESG important for pharmaceutical companies?
ESG can affect environmental performance, operational costs, supply-chain expectations, risk management, customer relationships and access to business opportunities. Pharmaceutical companies also operate in highly regulated environments, making systematic governance, evidence and risk management particularly relevant.
How can ISO standards support ESG in pharma?
ISO-based management systems can provide established processes for governance, risk-based thinking, objectives, monitoring, corrective action and continual improvement. For example, ISO 14001 can support environmental management, while ISO 9001 can provide useful process and improvement disciplines. They do not, however, automatically make an organization ESG-compliant.
Is EcoVadis mandatory for pharmaceutical companies?
EcoVadis is not universally mandatory for pharmaceutical companies. Its relevance depends on customer, supply-chain and stakeholder requirements. Where an organization participates in an EcoVadis assessment, having documented policies, implemented processes, measurable performance and supporting evidence can help it respond systematically.
How should pharmaceutical companies begin their ESG journey?
A practical starting point is an ESG gap assessment. The company can identify applicable requirements, relevant ESG topics, existing controls, data availability, supplier risks and documentation gaps. These findings can then be converted into prioritized actions, ownership, KPIs and implementation timelines.
How does ESG connect with supply-chain management?
ESG can be incorporated into supplier selection, due diligence, contractual requirements, supplier questionnaires, risk classification and improvement programs. A risk-based approach allows organizations to focus more detailed ESG assessment on suppliers whose products, geography, operations or strategic importance create greater exposure.
Can ESG initiatives reduce operating costs?
Some ESG initiatives can produce financial benefits, particularly projects involving energy efficiency, resource efficiency, waste reduction or process improvement. The financial impact should be calculated using the organization’s actual baseline costs, production conditions, investment requirements and verified performance rather than assumed savings.
Author Bio
Swati Khire — ISO Lead Auditor | NEBOSH HSE Professional | ESG Expert | EcoVadis Consultant
Swati Khire is an ISO Lead Auditor and ESG professional with expertise spanning management systems, health and safety, sustainability and EcoVadis-related consulting. Her perspective combines management-system discipline with practical ESG and sustainability considerations, helping organizations approach compliance, risk and continual improvement in a structured manner.
